APOE‐targeted epigenome therapy for late onset Alzheimer’s disease

There is an urgent need to refocus Alzheimer’s disease (AD) drug discovery on new targets and shifting the paradigm of AD DRUG DEVELOPMENT towards precision medicine. Apolipoprotein E gene (APOE) is the strongest and most reproduceable genetic risk factor for late‐onset Alzheimer’s disease (LOAD), and thus holds promise as a potential therapeutics target for LOAD. In this study we developed an epigenome therapy platform to reduce APOE expression generally and APOEe4 specifically by targeted modification of the epigenome landscape within APOE locus.